Impact of different fludarabine doses in the fludarabine-based conditioning regimen for unrelated bone marrow transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for patients with various hematological disorders1. Reduced-intensity conditioning (RIC) and myeloablative reduced-toxicity conditioning (RTC) regimens have been developed to reduce early non-relapse mortality (NRM) and complications associated with myeloablative conditioning (MAC) regimens. These regimens allow for the extension of HSCT to older and unsuitable patients who are unable to tolerate MAC regimens2-4. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 17, 2024 Category: Hematology Authors: Kodai Kuriyama, Shigeo Fuji, Ayumu Ito, Noriko Doki, Yuta Katayama, Hiroyuki Ohigashi, Tetsuya Nishida, Kentaro Serizawa, Tetsuya Eto, Naoyuki Uchida, Yoshinobu Kanda, Masatsugu Tanaka, Ken-ichi Matsuoka, Hideyuki Nakazawa, Junya Kanda, Takahiro Fukuda, Y Source Type: research
Comparison of psychological well-being, hope, and health concern in leukemia patients before and after receiving stem cells
CONCLUSION: Based on the research findings, it was concluded that receiving stem cells increases hope and psychological well-being in leukemia patients and significantly reduces health concerns.PMID:38361901 | PMC:PMC10866275 | DOI:10.4103/jfmpc.jfmpc_2360_22 (Source: Cancer Control)
Source: Cancer Control - February 16, 2024 Category: Cancer & Oncology Authors: Tahereh Yavari Amiryousef Zahedi Nima Movahednia Negin Hajhamidiasl Fariba Gheisvandi Fatemeh Sheyni Source Type: research
Comparison of psychological well-being, hope, and health concern in leukemia patients before and after receiving stem cells
CONCLUSION: Based on the research findings, it was concluded that receiving stem cells increases hope and psychological well-being in leukemia patients and significantly reduces health concerns.PMID:38361901 | PMC:PMC10866275 | DOI:10.4103/jfmpc.jfmpc_2360_22 (Source: Primary Care)
Source: Primary Care - February 16, 2024 Category: Primary Care Authors: Tahereh Yavari Amiryousef Zahedi Nima Movahednia Negin Hajhamidiasl Fariba Gheisvandi Fatemeh Sheyni Source Type: research
Comparison of psychological well-being, hope, and health concern in leukemia patients before and after receiving stem cells
CONCLUSION: Based on the research findings, it was concluded that receiving stem cells increases hope and psychological well-being in leukemia patients and significantly reduces health concerns.PMID:38361901 | PMC:PMC10866275 | DOI:10.4103/jfmpc.jfmpc_2360_22 (Source: Primary Care)
Source: Primary Care - February 16, 2024 Category: Primary Care Authors: Tahereh Yavari Amiryousef Zahedi Nima Movahednia Negin Hajhamidiasl Fariba Gheisvandi Fatemeh Sheyni Source Type: research
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
Bone Marrow Transplantation, Published online: 15 February 2024; doi:10.1038/s41409-024-02233-2Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 15, 2024 Category: Hematology Authors: Meera Mohan Aniko Szabo Anannya Patwari Jean Esselmann Tanvi Patel Ramya Bachu Lisa E. Rein Abhishek Janardan Vineel Bhatlapenumarthi Evanka Annyapu Catherine Skoog Areyl Goff Samer Al Hadidi Sabarinath Venniyil Radhakrishnan Sharmilan Thanendrarajan Maur Source Type: research
Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program
Bone Marrow Transplantation, Published online: 15 February 2024; doi:10.1038/s41409-024-02207-4Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 15, 2024 Category: Hematology Authors: Thirupathi Pattipaka S éverine Sarp Peyman Nakhaei Sibel G üneş Source Type: research
Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients
Bone Marrow Transplantation, Published online: 14 February 2024; doi:10.1038/s41409-024-02221-6Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 14, 2024 Category: Hematology Authors: Simona Piemontese Maria Teresa Lupo Stanghellini Federica Sora Simona Sica Jacopo Peccatori Magda Marcatti Elisabetta Metafuni Sabrina Giammarco Raffaella Greco Alessandro Bruno Fabio Ciceri Andrea Bacigalupo Patrizia Chiusolo Source Type: research
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis
Bone Marrow Transplantation, Published online: 14 February 2024; doi:10.1038/s41409-024-02238-xOutcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 14, 2024 Category: Hematology Authors: Alexandre E. Malek Taha Al-Juhaishi Den ái R. Milton Jeremy L. Ramdial May Daher Amanda L. Olson Samer A. Srour Gheath Alatrash Betul Oran Rohtesh S. Mehta Issa F. Khouri Qaiser Bashir Nina Shah Stefan O. Ciurea Gabriela Rondon Farzaneh Maadani Chitra Ho Source Type: research
A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma
Bone Marrow Transplantation, Published online: 14 February 2024; doi:10.1038/s41409-024-02231-4A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 14, 2024 Category: Hematology Authors: Asao Hirose Hideo Koh Mika Nakamae Yasuhiro Nakashima Mitsutaka Nishimoto Hiroshi Okamura Yosuke Makuuchi Masatomo Kuno Teruhito Takakuwa Kentaro Ido Kazuki Sakatoku Masayuki Hino Hirohisa Nakamae Source Type: research
Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma
Bone Marrow Transplantation, Published online: 14 February 2024; doi:10.1038/s41409-024-02229-yPeripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 14, 2024 Category: Hematology Authors: Yosuke Nakaya Hirohisa Nakamae Masashi Nishikubo Eisei Kondo Takahiro Fukuda Nobuhiro Hiramoto Yasuo Mori Koji Nagafuji Tetsuya Eto Yasushi Onishi Naoyuki Uchida Jun Ishikawa Ken-ichi Matsuoka Shunsuke Yui Ken Takase Toshiro Kawakita Junya Kanda Tatsuo Ic Source Type: research
Wine, witches and blood
Bone Marrow Transplantation, Published online: 13 February 2024; doi:10.1038/s41409-024-02235-0Wine, witches and blood (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 13, 2024 Category: Hematology Authors: Shaun R. McCann Source Type: research
Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation
Bone Marrow Transplantation, Published online: 13 February 2024; doi:10.1038/s41409-024-02232-3Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 13, 2024 Category: Hematology Authors: Giovanna Melica Elaina Preston Meighan Palazzo Kenneth Seier Florent Malard Christina Cho Sean M. Devlin Molly Maloy Taylor Borrill Peter Maslak Gunjan L. Shah Miguel-Angel Perales Source Type: research
Low dose post-transplant cyclophosphamide and sirolimus induce mixed chimerism with CTLA4-Ig or lymphocyte depletion in an MHC-mismatched murine allotransplantation model
Bone Marrow Transplantation, Published online: 12 February 2024; doi:10.1038/s41409-024-02237-yLow dose post-transplant cyclophosphamide and sirolimus induce mixed chimerism with CTLA4-Ig or lymphocyte depletion in an MHC-mismatched murine allotransplantation model (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 12, 2024 Category: Hematology Authors: Mariama D. Kabore Corbin C. McElrath Mohamed A. E. Ali Katherine Almengo Arunakumar Gangaplara Cameron Fisher Mauricio A. Barreto Ahmad Shaikh Purevdorj B. Olkhanud Xin Xu Deanna Gaskin Maria Lopez-Ocasio Ankit Saxena J. Philip McCoy Courtney D. Fitzhugh Source Type: research
Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation, Published online: 10 February 2024; doi:10.1038/s41409-024-02234-1Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - February 10, 2024 Category: Hematology Authors: Ryusuke Yamamoto Nobuhiro Hiramoto Ayumi Fujimoto Hirohito Yamazaki Takehiko Mori Naoyuki Uchida Noriko Doki Jun Kato Masashi Nishikubo Shinichi Kako Tetsuya Nishida Shuichi Ota Makoto Onizuka Tetsuya Eto Koichi Onodera Kazuhiro Ikegame Ken-ichi Matsuoka Source Type: research
